- Home
- ZGM vs KLRS Comparison
ZGM vs KLRS Comparison
Compare ZGM & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZGM
- KLRS
- Stock Information
- Founded
- ZGM 2019
- KLRS 2019
- Country
- ZGM Macau
- KLRS United States
- Employees
- ZGM N/A
- KLRS N/A
- Industry
- ZGM Professional Services
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZGM Consumer Discretionary
- KLRS Health Care
- Exchange
- ZGM Nasdaq
- KLRS Nasdaq
- Market Cap
- ZGM 43.6M
- KLRS 46.0M
- IPO Year
- ZGM 2025
- KLRS N/A
- Fundamental
- Price
- ZGM $4.00
- KLRS $7.68
- Analyst Decision
- ZGM
- KLRS Strong Buy
- Analyst Count
- ZGM 0
- KLRS 2
- Target Price
- ZGM N/A
- KLRS $23.00
- AVG Volume (30 Days)
- ZGM 277.2K
- KLRS 224.3K
- Earning Date
- ZGM 01-01-0001
- KLRS 11-15-2025
- Dividend Yield
- ZGM N/A
- KLRS N/A
- EPS Growth
- ZGM 401.52
- KLRS N/A
- EPS
- ZGM 0.17
- KLRS N/A
- Revenue
- ZGM $3,620,780.00
- KLRS N/A
- Revenue This Year
- ZGM N/A
- KLRS N/A
- Revenue Next Year
- ZGM N/A
- KLRS N/A
- P/E Ratio
- ZGM $23.39
- KLRS N/A
- Revenue Growth
- ZGM 211.78
- KLRS N/A
- 52 Week Low
- ZGM $2.00
- KLRS $2.14
- 52 Week High
- ZGM $4.51
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- ZGM N/A
- KLRS 67.13
- Support Level
- ZGM N/A
- KLRS $4.41
- Resistance Level
- ZGM N/A
- KLRS $8.80
- Average True Range (ATR)
- ZGM 0.00
- KLRS 0.89
- MACD
- ZGM 0.00
- KLRS 0.23
- Stochastic Oscillator
- ZGM 0.00
- KLRS 69.46
About ZGM Zenta Group Company Limited Ordinary Shares
Zenta Group Co Ltd is engaged in the provision of industrial park consultation services, business investment consultation services to clients through LIC, and sales of fintech products and services through LFT. Its industrial park consultation services are focused on the pre-development stage. Its business investment consultation services, offered through LIC, mainly focus on assisting clients to acquire stakes in specific investments, and it's normally in the form of equity ownership.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.